-
公开(公告)号：EP0652956A1
公开(公告)日：1995-05-17
申请号：EP92901011.0
申请日：1991-12-16
摘要： A purified antigen of T. gondii having a molecular weight of 54-kDa (as determined by Western blotting) is provided which is reactive with antibodies raised against a recombinant protein obtained by expression of a defined T. gondii cDNA (Figure 2) in a host cell; also provided are immunogenic fragments of the 54-kDa antigen. Recombinant DNA encoding the 54-kDa antigen, host cells for expression of such DNA, a vaccine for treating or preventing toxoplasmosis infection in humans and animals, and test kits for detection of T. gondii antigen or antibody are also described.
-
92.发明公开HEPATITIS VACCINES CONTAINING 3-O-DEACYLATED MONOPHOSHORYL LIPID A 失效3-0脱酰基脂质A Monophosphoril含有肝炎疫苗。
公开(公告)号：EP0633784A1
公开(公告)日：1995-01-18
申请号：EP93906601.0
申请日：1993-03-24
发明人： GARCON-JOHNSON, Nathalie Marie-Josephe Claude , HAUSER, Pierre, SmithKline Beecham Biol. (s.a.) , THIRIART, Clothilde, Smithline Beecham Biol.(s.a) , VOET, Pierre, SmithKline Beecham Biol. (s.a.)
CPC分类号： A61K39/39 , A61K39/12 , A61K39/29 , A61K39/292 , A61K2039/5252 , A61K2039/55505 , A61K2039/55572 , A61K2039/70 , C12N2730/10134 , C12N2770/32434 , Y02A50/464 , Y02A50/466
摘要： A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.
-
93.发明公开HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN GD AND 3 DEACYLATED MONOPHOSPHORYL LIPID A 失效单纯疱疹疫苗，THE HSV糖蛋白gD和3-脱酰基单磷酰脂质A含有。
公开(公告)号：EP0576478A1
公开(公告)日：1994-01-05
申请号：EP92906441.0
申请日：1992-03-17
发明人： FRANCOTTE, Myriam , PRIEELS, Jean-Paul , SLAOUI, Moncef , GARCON-JOHNSON, Nathalie, Marie-Josephe, Claude
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/541 , A61K2039/545 , A61K2039/55505 , A61K2039/55566 , A61K2039/55572 , A61K2039/57 , C12N2710/16634
摘要： On décrit de nouvelles formulations de vaccin contre le virus de l'herpès simplex (HSV) comprenant la glycoprotéine gD du HSV ou des fragments immunologiques conjugués avec le lipide A de monophosphoryle 3-déacylé.
-
公开(公告)号：EP0352250A3
公开(公告)日：1990-11-14
申请号：EP89870113.1
申请日：1989-07-20
发明人： Capiau, Carine , Locht, Camille
CPC分类号： C07K14/235 , A61K39/00 , C12N15/74
摘要： A vaccine for protection against whooping cough which comprises protein encoded by a B. pertussis toxin amino acid coding sequence containing an entire or truncated B. pertussis toxin S1 subunit amino acid coding sequence which contains a modification of the tryptophan residue at amino acid position 26.
摘要翻译： 一种用于预防百日咳的疫苗，其包含由百日咳博德特氏菌毒素氨基酸编码序列编码的蛋白质，所述氨基酸编码序列包含完整或截短的百日咳博德特氏菌毒素S1亚基氨基酸编码序列，其含有在氨基酸位置26处的色氨酸残基的修饰。
-
95.发明授权Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B 有权与乙型流感嗜血杆菌的低剂量的多价疫苗组合物
公开(公告)号：EP1946769B1
公开(公告)日：2012-05-30
申请号：EP07116669.8
申请日：2001-06-27
发明人： Boutriau, Dominique , Capiau, Carine , Desmons, Pierre Michel , Lemoine, Dominique , Poolman, Jan
IPC分类号： A61K39/116 , A61K39/295 , A61K39/385
CPC分类号： A61K39/102 , A61K2039/545 , A61K2039/6037 , Y02A50/466 , Y02A50/484
摘要： A multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.
-
96.发明公开Hyperblebbing bacterial strains and use thereof for production of vaccines 审中-公开Hyperblebbing“细菌菌株及其对疫苗的制备使用
公开(公告)号：EP2141227A3
公开(公告)日：2010-08-11
申请号：EP09165364.2
申请日：2002-02-08
发明人： Berthet, Francois-Xavier Jacques , Denoel, Philippe , Neyt, Cecile Anne , Poolman, Jan , Thonnard, Joelle
IPC分类号： C12N1/21 , C07K14/22 , C07K14/285 , C07K14/195 , A61K39/095 , A61K39/10 , A61K39/102 , A61K39/104 , A61K39/106
CPC分类号： C07K14/285 , A61K2039/52 , C07K14/195 , C07K14/22 , C12N1/20 , Y02A50/484
摘要： The present invention relates to the field of, engineered Gram-negative bacterial strains that have outer-membrane vesicle shedding properties, and vaccine compositions comprising these bacteria or vesicles. The present invention provides a hyperblebbing Gram-negative bacterium which has been genetically modified by either or both processes selected from a group consisting of: down- regulation of expression of one or more tol genes; and mutation of one or more gene(s) encoding a protein comprising a peptidoglycan-associated site to attenuate the peptidoglycan-binding activity of the protein(s).
-
97.发明公开
公开(公告)号：EP1946769A2
公开(公告)日：2008-07-23
申请号：EP07116669.8
申请日：2001-06-27
发明人： Boutriau, Dominique , Capiau, Carine , Desmons, Pierre Michel , Lemoine, Dominique , Poolman, Jan
IPC分类号： A61K39/116 , A61K39/295 , A61K39/385
CPC分类号： A61K39/102 , A61K2039/545 , A61K2039/6037 , Y02A50/466 , Y02A50/484
摘要： A multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.
摘要翻译： 描述了一种多价疫苗组合物，其包含全细胞百日咳组分，破伤风类毒素，白喉类毒素和低剂量流感嗜血杆菌b的荚膜多糖的缀合物。
-
公开(公告)号：EP1618889A3
公开(公告)日：2006-06-14
申请号：EP05077465.2
申请日：2000-09-27
发明人： D'Hondt, Erik , Hehme, Norbert
IPC分类号： A61K39/145 , A61P31/12
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/54 , A61K2039/543 , A61K2039/55505 , C07K14/005 , C12N2760/16122 , C12N2760/16151 , C12N2760/16222 , C12N2760/16234 , C12N2760/16251
摘要： The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.
-
公开(公告)号：EP1309344A1
公开(公告)日：2003-05-14
申请号：EP01965535.6
申请日：2001-08-14
CPC分类号： A61K9/0053 , A61K9/2095 , A61K2039/541 , Y02A50/386 , Y02A50/412
摘要： The present invention relates to novel vaccine formulations suitable for oral administration. The vaccine formulations are in a solid form comprising antigen and suitable excipients, which after insertion into the mouth, rapidly dissolve in saliva, thereby releasing the vaccine into the mouth. Specifically, the solid form may consist of a cake of vaccine which is formed from a liquid solution or suspension by sublimation, preferably sublimation by lyophilisation. Preferred vaccines are those containing antigens which are or are derived from pathogens that normally infect or invade the host through a mucosal membrane, or those vaccines that further comprise an antacid. Particularly preferred vaccines are combination vaccines that comprise more than one antigen, and more preferably when the antigens are from more than one pathogen.
-
公开(公告)号：EP1301238A1
公开(公告)日：2003-04-16
申请号：EP01962862.7
申请日：2001-07-18
发明人： DALTON, Colin Clive,GlaxoSmithKline Biologicals , EASEMAN, Richard Lewis,GlaxoSmithKline , GARCON, Nathalie,GlaxoSmithKline Biologicals
IPC分类号： A61M37/00
CPC分类号： A61K39/00 , A61B17/205 , A61K9/0021 , A61K9/19 , A61K39/0012 , A61K47/26 , A61K2039/54 , A61K2039/55577 , A61K2039/6037 , A61M37/0015 , A61M2037/0023 , A61M2037/003 , A61M2037/0038 , A61M2037/0046 , A61M2037/0053 , C07K14/775
摘要： The present invention relates to efficient devices for administration of pharmaceutical agents into the skin of the human body. In particular the present invention provides devices for vaccination into the skin. The present invention provides a pharmaceutical agent delivery device having skin-piercing portion comprising a solid reservoir medium containing the pharmaceutical agent, wherein the reservoir medium is coated onto the skin piercing portion. alternatively, the skin piercing portion may consist of the solid pharmaceutical agent reservoir medium. The pharmaceutical delivery devices are proportioned such that agent is delivered into defined layers of the skin, and preferred delivery devices comprise skin-piercing portions that deliver the pharmaceutical agent into the epithelium or the dermis. Preferred reservoir media comprise sugars, and in particular stabilising sugars that forms a glass such as lactose, raffinose, trehalose or sucrose. Furthermore, vaccine delivery devices for administration of vaccines into the skin are provided, methods of their manufacture, and their use in medicine.
-
-
-
-
-
-
-
-
-
搜索结果
246 条记录 (耗时 0.019 秒)
